Novel 18F-FES PET/CT in Non-invasive Functional Diagnosis of Delayed Lung Metastasis Presented with Horner Syndrome in a Metastatic Breast Cancer Patient
Abstract
Hormonal receptor positive human epidermal receptor 2 negative (HR+/HER2-) is the commonest molecular subtype of breast cancer (BC). Patients with HR+/HER2- BC may manifest clinically a late recurrence whose BC metastasizes 10-15 years post-operatively. We report one case who presented with pulmonary mass in upper lobe of lung and Horner syndrome 16 years after BC surgery. FDG PET/CT suggested pulmonary malignancy but could not differentiate between primary or metastatic cancer when invasive biopsy was quite risky. Novel 18F-FES PET/CT facilitated the non-invasive functional diagnosis of estrogen-receptor positive (ER+) pulmonary metastasis of BC, and the patient experienced partial response (PR) after CDK4/6 inhibitor and aromatase inhibitor as endocrine therapy. This article reviews the diagnosis and treatment process of this case, to provide guidance for non-invasive global evaluation of ER status among metastatic HR+/HER2- BC patients with 18F-FES PET/CT.
References
Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
Xu B H, Wang S S, Jiang Z F, et al. Expert consensus on maintenance treatment of advanced breast cancer in China[J]. Natl Med J China, 2018, 98(2): 87-90.
Breast Cancer Expert Committee of National Cancer Quality Control Center, Breast Cancer Expert Committee of China Anti-Cancer Association, Cancer Drug Clinical Research Committee of China Anti-Cancer Association. Guidelines for clinical diagnosis and treatment of advanced breast cancer in China (2020 Edition)[J]. Chin J Oncol, 2020, 42(10): 781-797.
Pedersen R N, Esen B Ö, Mellemkjær L, et al. The incidence of breast cancer recurrence 10-32 years after primary diagnosis[J]. J Natl Cancer Inst, 2022, 114(3): 391-399.
Rueda O M, Sammut S J, Seoane J A, et al. Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups[J]. Nature, 2019, 567(7748): 399-404.
Glass C C, Pride R M, Freedman R A, et al. Racial disparities in locoregional recurrence in postmenopausal patients with stage Ⅰ-Ⅲ, hormone receptor-positive breast cancer enrolled in the NSABP B-42 clinical trial[J]. Ann Surg Oncol, 2023, 30(13): 8320-8326.
Shen S J, Han Z J, Yu S N, et al. Breast cancer with malignant pulmonary nodules: pulmonary metastasis of breast cancer? Is it breast and lung dual primary cancer?[J]. Med J PUMCH, 2020, 11(1): 109-114.
Peterson L M, Kurland B F, Schubert E K, et al. A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC)[J]. Mol Imaging Biol, 2014, 16(3): 431-440.
Chae S Y, Ahn S H, Kim S B, et al. Diagnostic accuracy and safety of 16α-[18F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study[J]. Lancet Oncol, 2019, 20(4): 546-555.
Van Geel J J L, Boers J, Elias S G, et al. Clinical validity of 16α-[18F]fluoro-17β-estradiol positron emission tomography/computed tomography to assess estrogen receptor status in newly diagnosed metastatic breast cancer[J]. J Clin Oncol, 2022, 40(31): 3642-3652.
Pan B, Hao Z X, Zhou Y D, et al. Increased 18 F-fluoroestradiol uptake of radiation pneumonitis in a patient with metastatic breast cancer[J]. Clin Nucl Med, 2023, 48(5): 437-438.
Pan B, Hao Z X, Xu Y, et al. Case report: 18F-FES PET/CT predicted treatment responses of second-line and third-line CDK4/6 inhibitors after disease progression on first-line CDK4/6 inhibitor in a HR+/HER2- metastatic breast cancer patient[J]. Front Oncol, 2022, 12: 1095779.
Sledge G W, Jr, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial[J]. JAMA Oncol, 2020, 6(1): 116-124.
Goetz M P, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer[J]. J Clin Oncol, 2017, 35(32): 3638-3646.
Finn R S, Martin M, Rugo H S, et al. Palbociclib and letrozole in advanced breast cancer[J]. N Engl J Med, 2016, 375(20): 1925-1936.
Cristofanilli M, Turner N C, Bondarenko I, et al. Fulves-trant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial[J]. Lancet Oncol, 2016, 17(4): 425-439.
Tripathy D, Im S A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial[J]. Lancet Oncol, 2018, 19(7): 904-915.
Lu Y J, Tong Y W, Chen X S, et al. Association of biomarker discrepancy and treatment decision, disease outcome in recurrent/metastatic breast cancer patients[J]. Front Oncol, 2021, 11: 638619.
Boers J, Loudini N, De Haas R J, et al. Analyzing the estrogen receptor status of liver metastases with[18F]-FES-PET in patients with breast cancer[J]. Diagnostics (Basel), 2021, 11(11): 2019.
京公网安备11010802044758号